NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Gro,

Thanks for explaining the significance of the P3 for us again.






Fact ✅️:
1. The P3 is only one of the trials relevant to NWBO.
2. BP is already involved.
3. The U.S. NIH & U.S. DoD are involved.
4. NWBO owns licenses for other technologies that were not part of the P3.
5. The P3 was an exemplary trial for a challenging disease—it was clinically appropriate and compassionate.
6. FDA approved the P3 to commence, restart, and the FDA approved the trial to advance to phase 3.

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/


Beyond the landmark DCVax-L PIII, combos are now emerging as the new focus!

DCVax-L is currently being studied in a placebo-controlled RCT that has reached PII at UCLA.

Additionally, we also have more than one DC platform to consider (aDC1 at Roswell is also being studied in combo with Keytruda).

DCVax-L Keytruda Combo:
☑️ Ongoing pembrolizumab & Hiltonol (poly-ICLC) Trial with DCVax-L
https://www.clinicaltrials.gov/study/NCT04201873


ASM June 29, 2024

NICE UK 🇬🇧 DCVax-L

AI Fact-Checking